Skip to content


BMC Proceedings

Open Access

MFSD2A is a novel lung tumour suppressor gene whose expression is modulated by a 5’-region polymorphism

  • Francesca Colombo1Email author,
  • Monica Spinola1, 2,
  • Felicia S Falvella1,
  • James P Sullivan2,
  • David S Shames2,
  • Luc Girard2,
  • Paola Spessotto3,
  • John D Minna2 and
  • Tommaso A Dragani1
BMC Proceedings20104(Suppl 2):P55

Published: 24 September 2010

MFSD2A gene maps on chromosome 1p34, within a linkage disequilibrium block containing genetic elements associated with progression of lung cancer, even if with some discrepancies in Asian and Caucasian populations attributable to ethnic differences in allelic frequencies of the functional genetic variations mapping in this locus. Here we show that MFSD2A expression is strongly downregulated in non-small cell lung cancer cell lines of different histotypes and in primary lung adenocarcinomas. Investigating, by luciferase reporter assay, three single nucleotide polymorphisms (SNPs), mapping in MFSD2A 5’-regulatory region, for their putative effects on gene transcription, we find that rs12072037 SNP (polymorphic in Asians, but not in Caucasian) is able to modulate transcriptional activity of MFSD2A promoter in cell lines expressing transcription factors potentially binding to the SNP site. Microarray analysis showed that MFSD2A upregulation modulates transcript levels of genes involved in cell cycle control and interaction with the extracellular matrix. Exogenous expression of MFSD2A induced a significant reduction of tumour colony number in vitro and tumour volume in vivo. In addition, lung tumour cells transfected with MFSD2A were blocked at the G1 phase of cell cycle progression and showed impaired adhesion and migration in vitro. Together, these data suggest that MFSD2A is a novel tumour suppressor gene that regulates cell cycle progression and matrix attachment. The functional variation in MFSD2A 5’-region influencing promoter activity may be involved in modulation of MFSD2A transcript levels in normal and lung tumours, and be associated with lung cancer progression.

Authors’ Affiliations

Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
University of Texas Southwestern Medical Center, Dallas, USA
Centro di Riferimento Oncologico di Aviano, Aviano, Italy


© Colombo et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.